These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 31438996)

  • 21. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
    Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
    Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for
    Yang Z; Liang SQ; Yang H; Xu D; Bruggmann R; Gao Y; Deng H; Berezowska S; Hall SRR; Marti TM; Kocher GJ; Zhou Q; Schmid RA; Peng RW
    Cancer Res; 2021 Jun; 81(11):3121-3133. PubMed ID: 33685992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
    Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
    J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
    Yamani A; Zdżalik-Bielecka D; Lipner J; Stańczak A; Piórkowska N; Stańczak PS; Olejkowska P; Hucz-Kalitowska J; Magdycz M; Dzwonek K; Dubiel K; Lamparska-Przybysz M; Popiel D; Pieczykolan J; Wieczorek M
    Eur J Med Chem; 2021 Jan; 210():112990. PubMed ID: 33199155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
    Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
    BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
    Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
    Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.
    Akhand SS; Liu Z; Purdy SC; Abdullah A; Lin H; Cresswell GM; Ratliff TL; Wendt M
    Cancer Immunol Res; 2020 Dec; 8(12):1542-1553. PubMed ID: 33093218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
    Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
    Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer.
    Abdullah A; Akhand SS; Paez JSP; Brown W; Pan L; Libring S; Badamy M; Dykuizen E; Solorio L; Andy Tao W; Wendt MK
    Oncogene; 2021 Jan; 40(2):322-333. PubMed ID: 33128042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
    Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
    Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
    Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
    Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling.
    Suh J; Kim DH; Lee YH; Jang JH; Surh YJ
    Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
    Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
    Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
    Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
    Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The c.1085A>G Genetic Variant of
    Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
    Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
    [No Abstract]   [Full Text] [Related]  

  • 37. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
    SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
    Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
    Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
    Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.